AstraZeneca is partnering with leading organisations in Singapore to support research into new and more targeted therapies for heart failure.

The drug giant is linking with a number of groups - including the Agency for Science, Technology and Research, National University Heart Centre, Singapore and National University of Singapore - in a two-year collaboration that will focus on clearer understanding of the pathophysiology of heart failure in patients with preserved ejection fraction (HFpEF), a complex syndrome for which there is currently no effective treatment.

Heart failure is the leading cause of cardiovascular hospitalisation worldwide, and around half of patients suffer from HFpEF, which occurs when the heart chambers are unable to relax and fill with blood as they normally do and less blood is pumped out to organs and tissues in the body.

The alliance seeks to distinguish between subsets of heart failure patients and identify the molecular pathway leading to HFpEF, so that biomarkers can be established that might form the basis of new treatments. Findings will also be integrated into AZ’ broader cardiovascular research programme.